Quantcast

Latest Nicholas J. Vogelzang Stories

2010-05-20 18:13:00

THE WOODLANDS, Texas, May 20 /PRNewswire/ -- US Oncology, Inc., the nation's leading integrated oncology company, announced today that two physicians affiliated with US Oncology Research will be honored at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 4 - 8 at McCormick Place in Chicago. (Photo: http://www.newscom.com/cgi-bin/prnh/20100520/DA08694) Daniel D. Von Hoff, MD, FACP, is the recipient of the 2010 David A. Karnofsky Memorial Award and...

2010-04-30 11:11:17

2nd European Lung Cancer Conference The first trial of an important new combination therapy of treatment with the chemotherapy drug pemetrexed concurrent with radiation in lung cancer has delivered promising results, French researchers report at the 2nd European Lung Cancer Conference. The results of the Phase I trial suggest that pemetrexed, unlike some other modern chemotherapy drugs, is well-enough tolerated to allow it to be administered at high dose with concurrent radiotherapy,...

2009-09-29 07:05:00

Perifosine Continues to Demonstrate Impressive Efficacy, Safety and Tolerability in Metastatic Renal Cell Carcinoma Patients who Progressed after Failing Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor QUEBEC CITY, Sept. 29 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX),...

2009-09-29 07:00:00

NEW YORK, Sept. 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced updated clinical results from a Phase 2 study of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single-agent treatment for advanced metastatic renal cell carcinoma (RCC). Dr. Thomas E. Hutson, Director of the Genitourinary Oncology Program at Baylor-Sammons Cancer Center in Dallas, Texas, presented the data on Saturday, September 26th, in an oral...

2009-09-14 07:30:00

NEW YORK, Sept. 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009. Dr. Thomas E. Hutson, Director of the Genitourinary Oncology Program...

2009-08-12 10:04:00

THE WOODLANDS, Texas, Aug. 12 /PRNewswire/ -- Medical oncologist and renowned cancer researcher Nicholas J. Vogelzang, M.D. has joined the US Oncology Research network and will treat patients at Comprehensive Cancer Centers of Nevada (CCCN), an affiliate of US Oncology, Inc. Dr. Vogelzang will serve as Chair and Medical Director of the Developmental Therapeutics Committee for US Oncology Research and Co-Chair of the Genitourinary Committee. The US Oncology Research network has a long...

2009-07-06 09:56:37

The U.S. Food and Drug Administration announced approval of Alimta, the first drug available for maintenance therapy of metastatic lung cancer. The FDA said patients with cancer often receive maintenance therapy to prevent the disease from progressing after their tumor has shrunk or the disease has stabilized in response to chemotherapy. Alimta (pemetrexed) disrupts metabolic processes that are dependent on the B-vitamin folate, a necessary ingredient for cell replication, the agency said....

2009-05-19 06:00:00

Partner Keryx to present Phase 2 data on perifosine for multiple cancers QUEBEC CITY, May 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108, in prostate cancer, will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be...

2008-09-30 09:00:18

TORONTO, Sept. 30 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced changes to its Board of Directors. Dr.ӚÓš EdӚÓš Miller, the Dean and Chief Executive Officer of Johns Hopkins University School of...

2008-07-16 06:00:13

By Annette Wells By ANNETTE WELLS REVIEW-JOURNAL Randy Irwin is the ultimate guinea pig. He's the first to try out an experimental treatment by New Jersey- based Medarex for kidney cancer to determine whether it works and to observe possible side effects. Hopes were that his tumor would shrink or disappear - or at the very least remain in check - because of the treatment. But earlier this month the 50-year-old Las Vegas resident learned that, after three treatments in six weeks,...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.